In draft guid­ance, NICE fails to back Clo­vis's PARP in­hibitor Rubra­ca

De­spite the EMA’s en­dorse­ment of Clo­vis’s can­cer treat­ment Rubra­ca last year, the UK’s cost-ef­fec­tive­ness watch­dog NICE has rec­om­mend­ed against the adop­tion of the drug in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER